Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Serotoninergic antidepressants positively affect platelet ADAM10 expression in patients with Alzheimer's disease

Full text
Fernandes Marques Bianco, Otavio Augusto ; Manzine, Patricia Regina ; Crispim Nascimento, Carla Manuela ; Carvalho Vale, Francisco Assis ; Iost Pavarini, Sofia Cristina ; Cominetti, Marcia Regina
Total Authors: 6
Document type: Journal article
Source: INTERNATIONAL PSYCHOGERIATRICS; v. 28, n. 6, p. 939-944, JUN 2016.
Web of Science Citations: 5

Background: Studies have demonstrated a decreased platelet ADAM10 expression in patients with Alzheimer's Disease (AD), classifying this protein as a blood-based AD biomarker. About 50% of the patients with AD are diagnosed with depression, which is commonly treated with tricyclic and tetracyclic antidepressants, monoaminoxidade (MAO) inhibitors and, more preferably, with selective serotonin reuptake inhibitors (SSRIs). Considering that a large proportion of patients with AD takes antidepressant medications during the course of the disease we investigated the influence of this medication on the expression of platelet ADAM10, which is considered the main alpha-secretase preventing beta-amyloid (beta A) formation. Methods: Blood was collected for protein extraction from platelets. ADAM10 was analyzed by using western blotting and reactive bands were measured using beta-actin as endogenous control. Results: Platelet ADAM10 protein expression in patients with AD was positively influenced by serotoninergic medication. Conclusion: More studies on the positive effects of serotonergic antidepressants on ADAM10 platelet expression should be performed in order to understand its biological mechanisms and to verify whether these effects are reflected in the central nervous system. This work represents an important advance for the study of AD biomarkers, as well as for more effective pharmacological treatment of patients with AD and associated depression. (AU)

FAPESP's process: 14/21066-2 - Gene expression of inflammatory cytokine and of microRNA as potential biomarkers of frailty in elderly inserted in a social vulnerability context.
Grantee:Carla Manuela Crispim Nascimento
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 12/01936-7 - Influence of antidepressants on ADAM10 platelet levels in Alzheimer's disease
Grantee:Otávio Augusto Fernandes Marques Bianco
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 12/08654-7 - Blood biomarkers for Alzheimer's Disease: evaluation of ADAM10 gene expression and micro-RNAs
Grantee:Patricia Regina Manzine Moralles
Support type: Scholarships in Brazil - Doctorate
FAPESP's process: 13/06879-4 - Blood biomarkers for Alzheimer's Disease: evaluation of ADAM10 gene expression and microRNAs
Grantee:Márcia Regina Cominetti
Support type: Regular Research Grants
FAPESP's process: 10/09497-7 - Platelet levels of ADAM10 in tracking Alzheimer's disease: contributions for nursing care
Grantee:Sofia Cristina Iost Pavarini
Support type: Regular Research Grants